Format

Send to

Choose Destination
J Cancer Res Ther. 2019 Jul-Sep;15(5):1051-1056. doi: 10.4103/jcrt.JCRT_1275_16.

Favorable results of patients with pT1a, b, c, lymph node-negative early breast cancer in the long interval.

Author information

1
Department of Medical Oncology, Kanuni Sultan Suleyman Education and Search Hospital, Ankara, Turkey.
2
Department of Medical Oncology, Ataturk Education and Search Hospital, Ankara, Turkey.
3
MKA Clinic Center, Tepe Prime, Ankara, Turkey.

Abstract

Background:

The clinical characteristics of patients who had lymph node-negative early breast cancer were assessed.

Patients and Methods:

We assessed a total of 576 patients in the study, including 74 patients (12.8%) with T1a, 119 patients (20.7%) T1b, and 367 patients (63.7%) with T1c. Patients with T1 tumors were further classified into three groups according to hormone receptor (HR) and human epidermal growth factor-receptor 2 (HER2) status.

Results:

In patients with T1a, the disease-free survival (DFS) rate was 98.4% at 2 years (P = 0.001). In subgroup analysis of early breast cancers, 10-year-DFS rates of the patients in HR+/HER2-, HR-/HER2+, and HR-/HER2- subgroups were not significantly different (P = 0.917).

Conclusion:

The T1a group had a worse prognosis than T1b and T1c groups in second years (P = 0.001); however, there was not statistically important difference between HR+, HER2+ and triple negative subgroups (P = 0.917). Although there are differences in patients and tumor features, the prognosis of patients with T1a, b, c N0M0 breast cancer is excellent.

KEYWORDS:

Early breast cancer; T1a; b; c; treatment

PMID:
31603109
DOI:
10.4103/jcrt.JCRT_1275_16
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center